Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market

Chemotherapy-Induced Nausea and Vomiting (CINV) Comprehensive Study by Type (CINV, PONV), Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), Patient Pool Type (Aloxi, Kytril, Emend, Netupitant-Palonosetron, Others), Route of Administration (Oral, Intravenous) Players and Region - Global Market Outlook to 2028

Chemotherapy-Induced Nausea and Vomiting (CINV) Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequently reported adverse events in patients receiving chemotherapy. If nausea and vomiting become severe, dehydration, metabolic disturbances, malnutrition, or aspiration pneumonia may occur. Treatments that prevent or reduce CINV are therefore an integrated part of the supportive care of cancer patients. According to Cancer Research UK, cancer caused almost 9.6 million deaths worldwide in 2018.

Highlights from Chemotherapy-Induced Nausea and Vomiting (CINV) Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledMerck & Co. (United States), Eisai (Japan), Kyowa Hakko Kirin Co. Ltd. (Japan), Helsinn Holding (Switzerland), Pfizer Inc. (United States), Mundipharma International (United Kingdom), Qilu Pharma (China), Teva Pharmaceutical Industries (Israel), Novartis (Switzerland) and Heron Therapeutics (United States)


Companies can differentiate themselves by investing in research and development to create innovative and more effective CINV treatments. This could involve developing new drug formulations, exploring novel mechanisms of action, or improving the delivery methods of existing drugs. Additionally, the players explore new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Chemotherapy-Induced Nausea and Vomiting (CINV) market throughout the forecasted period.

Merck & Co. (United States), Eisai (Japan), Kyowa Hakko Kirin Co. Ltd. (Japan), Helsinn Holding (Switzerland), Pfizer Inc. (United States), Mundipharma International (United Kingdom), Qilu Pharma (China), Teva Pharmaceutical Industries (Israel), Novartis (Switzerland) and Heron Therapeutics (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Roche Holding AG (Switzerland) and Mylan (United States).

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segmentation:
ScopeSub-Segments
Application / End UserHospitals, Ambulatory Surgical Centers and Diagnostic Centers
TypeCINV and PONV
Patient Pool TypeAloxi, Kytril,Emend,Netupitant-Palonosetron,Others
Route of AdministrationOral,Intravenous


On the basis of geography, the market of Chemotherapy-Induced Nausea and Vomiting (CINV) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Development and Launch of Novel Drug Delivery Methods for CINV Drugs and High Demand for Combination Therapy and Increasing Preference for Pressure Point Therapy

Market Growth Drivers:
Increase in adoption of chemotherapeutic drugs, Rise in the Incidence of Cancer Cases and Growing Healthcare Expenditure and Accelerating Economic Growth

Challenges:
Stringent Regulations and High Treatment Cost of Chemotherapy-Induced Nausea and Vomiting (CINV)

Restraints:
High Price of CINV Drugs

Opportunities:
Growth in the Number of Patients Undergoing Chemotherapy Drugs Treatment Across the World and Increasing Pharmaceutical R&D Spending

Key Target Audience
Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment, Chemotherapy-Induced Nausea and Vomiting (CINV) Association, Testing Laboratories, Research and Development Institutes, Financial Institutes and Investors, Regulatory Bodies and Others

Market Leaders & Development Strategies

In August 2016, Heron Therapeutics received U.S. FDA approval for SUSTOL, an extended-release injection of granisetron for the prevention of CINV.
In the United States, the Food and Drug Administration (FDA) is the regulatory authority responsible for approving and monitoring drugs for various conditions, including CINV. The FDA evaluates the safety and efficacy of drugs through a rigorous review process before granting approval for their use. They also continue to monitor drugs after approval to ensure their continued safety and effectiveness.

Report Objectives / Segmentation Covered

By Type
  • CINV
  • PONV
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
By Patient Pool Type
  • Aloxi, Kytril
  • Emend
  • Netupitant-Palonosetron
  • Others

By Route of Administration
  • Oral
  • Intravenous

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in adoption of chemotherapeutic drugs
      • 3.2.2. Rise in the Incidence of Cancer Cases
      • 3.2.3. Growing Healthcare Expenditure and Accelerating Economic Growth
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulations and High Treatment Cost of Chemotherapy-Induced Nausea and Vomiting (CINV)
    • 3.4. Market Trends
      • 3.4.1. The Development and Launch of Novel Drug Delivery Methods for CINV Drugs
      • 3.4.2. High Demand for Combination Therapy and Increasing Preference for Pressure Point Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chemotherapy-Induced Nausea and Vomiting (CINV), by Type, Application, Patient Pool Type, Route of Administration and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) (Value)
      • 5.2.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Type (Value)
        • 5.2.1.1. CINV
        • 5.2.1.2. PONV
      • 5.2.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Diagnostic Centers
      • 5.2.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Patient Pool Type (Value)
        • 5.2.3.1. Aloxi, Kytril
        • 5.2.3.2. Emend
        • 5.2.3.3. Netupitant-Palonosetron
        • 5.2.3.4. Others
      • 5.2.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Route of Administration (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Intravenous
      • 5.2.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) (Price)
      • 5.3.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Type (Price)
  • 6. Chemotherapy-Induced Nausea and Vomiting (CINV): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eisai (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Kyowa Hakko Kirin Co. Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Helsinn Holding (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mundipharma International (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Qilu Pharma (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Heron Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Sale, by Type, Application, Patient Pool Type, Route of Administration and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) (Value)
      • 7.2.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Type (Value)
        • 7.2.1.1. CINV
        • 7.2.1.2. PONV
      • 7.2.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Diagnostic Centers
      • 7.2.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Patient Pool Type (Value)
        • 7.2.3.1. Aloxi, Kytril
        • 7.2.3.2. Emend
        • 7.2.3.3. Netupitant-Palonosetron
        • 7.2.3.4. Others
      • 7.2.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Route of Administration (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Intravenous
      • 7.2.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) (Price)
      • 7.3.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chemotherapy-Induced Nausea and Vomiting (CINV): by Type(USD Million)
  • Table 2. Chemotherapy-Induced Nausea and Vomiting (CINV) CINV , by Region USD Million (2017-2022)
  • Table 3. Chemotherapy-Induced Nausea and Vomiting (CINV) PONV , by Region USD Million (2017-2022)
  • Table 4. Chemotherapy-Induced Nausea and Vomiting (CINV): by Application(USD Million)
  • Table 5. Chemotherapy-Induced Nausea and Vomiting (CINV) Hospitals , by Region USD Million (2017-2022)
  • Table 6. Chemotherapy-Induced Nausea and Vomiting (CINV) Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 7. Chemotherapy-Induced Nausea and Vomiting (CINV) Diagnostic Centers , by Region USD Million (2017-2022)
  • Table 8. Chemotherapy-Induced Nausea and Vomiting (CINV): by Patient Pool Type(USD Million)
  • Table 9. Chemotherapy-Induced Nausea and Vomiting (CINV) Aloxi, Kytril , by Region USD Million (2017-2022)
  • Table 10. Chemotherapy-Induced Nausea and Vomiting (CINV) Emend , by Region USD Million (2017-2022)
  • Table 11. Chemotherapy-Induced Nausea and Vomiting (CINV) Netupitant-Palonosetron , by Region USD Million (2017-2022)
  • Table 12. Chemotherapy-Induced Nausea and Vomiting (CINV) Others , by Region USD Million (2017-2022)
  • Table 13. Chemotherapy-Induced Nausea and Vomiting (CINV): by Route of Administration(USD Million)
  • Table 14. Chemotherapy-Induced Nausea and Vomiting (CINV) Oral , by Region USD Million (2017-2022)
  • Table 15. Chemotherapy-Induced Nausea and Vomiting (CINV) Intravenous , by Region USD Million (2017-2022)
  • Table 16. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2017-2022)
  • Table 17. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 18. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 19. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 20. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 21. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 22. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 23. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 24. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 25. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 26. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 27. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 28. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 29. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 30. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 31. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 32. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 33. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2017-2022)
  • Table 34. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 35. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 36. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 37. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 38. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 39. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 40. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 41. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 42. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 43. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 44. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 45. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 46. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 47. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 48. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 49. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 50. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 51. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 52. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 53. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 54. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 55. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 56. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 57. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 58. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 59. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 60. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 61. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 66. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2017-2022)
  • Table 67. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 68. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 69. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 70. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 71. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 72. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 73. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 74. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 75. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 76. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 77. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 78. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 79. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 80. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 81. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 82. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 83. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 84. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 85. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 86. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 87. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 88. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 89. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 90. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 91. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 92. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 93. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 94. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 95. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2017-2022)
  • Table 96. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 97. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 98. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 99. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 100. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 101. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 102. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 103. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 104. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 105. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 106. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 107. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 108. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2017-2022)
  • Table 109. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 110. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 111. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 112. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 113. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 114. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 115. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 116. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 117. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 118. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 119. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 120. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 121. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2017-2022)
  • Table 122. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2017-2022)
  • Table 123. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2017-2022)
  • Table 124. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2017-2022)
  • Table 125. Chemotherapy-Induced Nausea and Vomiting (CINV): by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Chemotherapy-Induced Nausea and Vomiting (CINV): by Type(USD Million)
  • Table 137. Chemotherapy-Induced Nausea and Vomiting (CINV) CINV , by Region USD Million (2023-2028)
  • Table 138. Chemotherapy-Induced Nausea and Vomiting (CINV) PONV , by Region USD Million (2023-2028)
  • Table 139. Chemotherapy-Induced Nausea and Vomiting (CINV): by Application(USD Million)
  • Table 140. Chemotherapy-Induced Nausea and Vomiting (CINV) Hospitals , by Region USD Million (2023-2028)
  • Table 141. Chemotherapy-Induced Nausea and Vomiting (CINV) Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 142. Chemotherapy-Induced Nausea and Vomiting (CINV) Diagnostic Centers , by Region USD Million (2023-2028)
  • Table 143. Chemotherapy-Induced Nausea and Vomiting (CINV): by Patient Pool Type(USD Million)
  • Table 144. Chemotherapy-Induced Nausea and Vomiting (CINV) Aloxi, Kytril , by Region USD Million (2023-2028)
  • Table 145. Chemotherapy-Induced Nausea and Vomiting (CINV) Emend , by Region USD Million (2023-2028)
  • Table 146. Chemotherapy-Induced Nausea and Vomiting (CINV) Netupitant-Palonosetron , by Region USD Million (2023-2028)
  • Table 147. Chemotherapy-Induced Nausea and Vomiting (CINV) Others , by Region USD Million (2023-2028)
  • Table 148. Chemotherapy-Induced Nausea and Vomiting (CINV): by Route of Administration(USD Million)
  • Table 149. Chemotherapy-Induced Nausea and Vomiting (CINV) Oral , by Region USD Million (2023-2028)
  • Table 150. Chemotherapy-Induced Nausea and Vomiting (CINV) Intravenous , by Region USD Million (2023-2028)
  • Table 151. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2023-2028)
  • Table 152. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 153. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 154. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 155. South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 156. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 157. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 158. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 159. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 160. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 161. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 162. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 163. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 164. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 165. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 166. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 167. Rest of South America Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 168. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2023-2028)
  • Table 169. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 170. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 171. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 172. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 173. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 174. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 175. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 176. China Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 177. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 178. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 179. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 180. Japan Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 181. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 182. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 183. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 184. India Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 185. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 186. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 187. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 188. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 189. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 190. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 191. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 192. Taiwan Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 193. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 194. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 195. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 196. Australia Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 197. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 198. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 199. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 201. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2023-2028)
  • Table 202. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 203. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 204. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 205. Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 206. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 207. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 208. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 209. Germany Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 210. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 211. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 212. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 213. France Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 214. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 215. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 216. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 217. Italy Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 218. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 219. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 220. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 221. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 222. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 223. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 224. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 225. Netherlands Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 226. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 227. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 228. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 229. Rest of Europe Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 230. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2023-2028)
  • Table 231. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 232. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 233. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 234. MEA Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 235. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 236. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 237. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 238. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 239. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 240. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 241. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 242. Africa Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 243. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Country USD Million (2023-2028)
  • Table 244. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 245. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 246. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 247. North America Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 248. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 249. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 250. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 251. United States Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 252. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 253. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 254. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 255. Canada Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 256. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Type USD Million (2023-2028)
  • Table 257. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Application USD Million (2023-2028)
  • Table 258. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Patient Pool Type USD Million (2023-2028)
  • Table 259. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV), by Route of Administration USD Million (2023-2028)
  • Table 260. Chemotherapy-Induced Nausea and Vomiting (CINV): by Type(USD/Units)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Type USD Million (2017-2022)
  • Figure 5. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Application USD Million (2017-2022)
  • Figure 6. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Patient Pool Type USD Million (2017-2022)
  • Figure 7. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Route of Administration USD Million (2017-2022)
  • Figure 8. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 9. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 10. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 11. MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 12. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 13. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Type USD/Units (2017-2022)
  • Figure 14. Global Chemotherapy-Induced Nausea and Vomiting (CINV) share by Players 2022 (%)
  • Figure 15. Global Chemotherapy-Induced Nausea and Vomiting (CINV) share by Players (Top 3) 2022(%)
  • Figure 16. Global Chemotherapy-Induced Nausea and Vomiting (CINV) share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 20. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Eisai (Japan) Revenue: by Geography 2022
  • Figure 22. Kyowa Hakko Kirin Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Kyowa Hakko Kirin Co. Ltd. (Japan) Revenue: by Geography 2022
  • Figure 24. Helsinn Holding (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Helsinn Holding (Switzerland) Revenue: by Geography 2022
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Mundipharma International (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Mundipharma International (United Kingdom) Revenue: by Geography 2022
  • Figure 30. Qilu Pharma (China) Revenue, Net Income and Gross profit
  • Figure 31. Qilu Pharma (China) Revenue: by Geography 2022
  • Figure 32. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 33. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2022
  • Figure 34. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 36. Heron Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 37. Heron Therapeutics (United States) Revenue: by Geography 2022
  • Figure 38. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Type USD Million (2023-2028)
  • Figure 39. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Application USD Million (2023-2028)
  • Figure 40. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Patient Pool Type USD Million (2023-2028)
  • Figure 41. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Route of Administration USD Million (2023-2028)
  • Figure 42. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 43. Asia Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 44. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 45. MEA Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 46. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Share (%), by Country
  • Figure 47. Global Chemotherapy-Induced Nausea and Vomiting (CINV): by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Merck & Co. (United States)
  • Eisai (Japan)
  • Kyowa Hakko Kirin Co. Ltd. (Japan)
  • Helsinn Holding (Switzerland)
  • Pfizer Inc. (United States)
  • Mundipharma International (United Kingdom)
  • Qilu Pharma (China)
  • Teva Pharmaceutical Industries (Israel)
  • Novartis (Switzerland)
  • Heron Therapeutics (United States)
Additional players considered in the study are as follows:
Roche Holding AG (Switzerland) , Mylan (United States)
Select User Access Type

Key Highlights of Report


May 2023 239 Pages 65 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Quantitative research analysis
Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increase in adoption of chemotherapeutic drugs " is seen as one of major growth factors of Chemotherapy-Induced Nausea and Vomiting (CINV) Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Chemotherapy-Induced Nausea and Vomiting (CINV) market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report?

Have a Query? Click Here

Other Related Reports

Erythropoietin Drugs Comprehensive Study by Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), Application (Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis), Others (...
$ 3450
Diaper Rash Cream Comprehensive Study by Type (Zinc Oxide-based, Zinc Oxide Free), Application (Hospitals and Clinics, Personal Care, Other), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy...
$ 3650
Pig Vaccine Comprehensive Study by Application (Veterinary Hospitals, Hog Production Farms), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjuga...
$ 3750
Intravenous Immunoglobulin (IVIg) Comprehensive Study by Type (Gammagard S/D, Gammagard Liquid, Gamunex, IGIVnex, Privigen, Others), Application (Neurology, Haematology, Immunology, Dermatology, Othe...
$ 3450
Fondaparinux Comprehensive Study by Type (Branded, Generic), Application (Home Care Settings, Hip/Knee Replacement, Cardiovascular, Abdominal Surgery, Other), Sales Channel (Third-Party Website, Manu...
$ 3650
Oxcarbazepine Drug Comprehensive Study by Type (Oxcarbazepine Tablet, Oral suspension), Application (Adult, Pediatric), Dosage (150 mg, 300 mg, 600 mg) Players and Region - Global Market Outlook to 2...
$ 3500